| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 |
|---|---|---|---|---|---|---|---|---|---|
Cash flows from operating activities: | |||||||||
Net loss | |||||||||
-7,580 | -7,691 | -5,369 | -7,294 | -5,539 | -1,707 | - | - | - | - |
Net income (loss) | |||||||||
- | - | - | - | - | - | 1,464 | -870 | -1,482 | -614 |
Adjustments to reconcile net loss to net cash used in operating activities: | |||||||||
Depreciation expense | |||||||||
47 | 66 | 62 | 92 | 27 | 17 | 18 | 18 | 22 | 45 |
Amortization of patents | |||||||||
53 | 814 | 510 | 70 | 69 | 78 | 77 | 76 | 83 | 83 |
Impairment to long lived assets | |||||||||
- | 1,539 | - | - | - | - | - | - | - | - |
Stock compensation | |||||||||
183 | 409 | 651 | 1,850 | - | - | - | - | - | - |
Amortization of debt discount | |||||||||
- | - | - | - | - | - | - | 3 | 5 | 2 |
Common stock and options for compensation, consulting and vendor services | |||||||||
- | - | - | - | 1,128 | 1,031 | 1,077 | 673 | 864 | 194 |
Bad debt reversal | |||||||||
- | - | - | - | - | - | -308 | - | - | - |
Increase in accrued interest for notes payable | |||||||||
- | - | - | - | - | - | - | 87 | 54 | - |
Bad debt reversal | |||||||||
- | - | - | - | - | - | - | -207 | -86 | 640 |
Loss on sale/disposal of equipment | |||||||||
- | - | - | - | - | - | - | -1 | - | - |
Loss on sale/disposal of equipment | |||||||||
- | - | - | - | - | - | - | - | - | 7 |
Loss (Income) from earnings on China joint venture | |||||||||
81 | 329 | -120 | -795 | -2,445 | -910 | - | -171 | -121 | - |
Gain on Dilutive Effect on Medical Joint Venture | |||||||||
- | - | - | - | - | - | 1,363 | - | - | - |
Write-off of Investment in German Distributor | |||||||||
- | - | - | - | - | - | - | 76 | - | - |
Inventory reserve | |||||||||
- | 543 | 219 | 0 | - | - | - | - | - | - |
Deferred cost reserve | |||||||||
- | 1,250 | - | - | - | - | - | - | - | - |
Change in fair value of derivative liability | |||||||||
-3,635 | - | - | - | - | - | - | - | - | - |
Amortization of right-of-use assets | |||||||||
155 | - | - | - | - | - | - | - | - | - |
Changes in operating assets and liabilities: | |||||||||
Decrease in accounts receivable | |||||||||
-267 | 442 | 733 | -635 | 207 | 8 | 126 | -525 | 172 | 734 |
Decrease in accounts receivable, related party | |||||||||
-100 | 192 | -989 | 1,727 | 0 | - | - | - | - | - |
Decrease in other receivables | |||||||||
9 | - | -10 | -48 | 58 | - | - | - | - | - |
(Increase) decrease in inventories | |||||||||
-300 | -914 | -1,003 | 509 | 875 | 1,175 | 683 | -151 | -196 | 182 |
(Increase) decrease in advances on contracts | |||||||||
61 | -48 | -3 | -514 | 450 | -1,587 | -519 | - | - | - |
Decrease to advances on contracts | |||||||||
- | - | - | - | - | - | - | -579 | - | - |
Decrease to advance to contracts | |||||||||
- | - | - | - | - | - | - | - | 962 | 1,981 |
Increase in prepaid expenses and other current assets | |||||||||
104 | -21 | 144 | -12 | -192 | 304 | -88 | -65 | -17 | -73 |
(Decrease) increase in accounts payable | |||||||||
320 | 227 | - | - | - | - | - | - | - | - |
Decrease in other assets | |||||||||
- | - | 9 | 0 | -2 | 1 | 5 | -20 | -47 | -120 |
(Decrease) increase in accounts payable | |||||||||
- | - | -363 | 486 | 173 | -516 | -316 | -1,594 | 607 | 2,169 |
(Decrease) increase in accounts payable, related party | |||||||||
-303 | 678 | -249 | 0 | - | - | - | - | - | - |
Decrease in deferred cost, related party | |||||||||
-50 | 191 | 489 | 620 | 0 | - | - | - | - | - |
Increase in accrued expenses | |||||||||
273 | 620 | 1,834 | - | - | - | -116 | 173 | 111 | -104 |
(Decrease) increase in accrued expenses, related party | |||||||||
1,228 | -108 | - | - | - | - | - | - | - | - |
Decrease in operating lease liability | |||||||||
-155 | - | - | - | - | - | - | - | - | - |
(Decrease) in deferred revenue, related party | |||||||||
-100 | 192 | 723 | - | - | - | - | - | - | - |
(Decrease) increase in accrued expenses and other payables | |||||||||
- | - | - | -755 | 220 | 466 | - | - | - | - |
Decrease in deferred revenue, related party | |||||||||
- | - | - | 1,001 | 0 | - | - | - | - | - |
Net cash used in operating activities | |||||||||
-1,779 | -1,628 | -1,229 | -5,398 | - | - | - | -49 | -570 | -293 |
Cash flows from investing activities: | |||||||||
Net cash used in operating activities | |||||||||
- | - | - | - | -2,946 | 376 | 1,258 | - | - | - |
Proceeds on sale of equipment | |||||||||
- | - | - | - | - | - | - | - | - | 2 |
Purchase of intangible assets | |||||||||
- | - | 39 | 15 | 9 | 16 | 21 | 26 | 31 | 80 |
Investment in Medical joint venture | |||||||||
- | - | - | - | - | - | 484 | - | - | - |
Purchase of property and equipment | |||||||||
9 | 7 | 6 | 15 | 67 | 82 | 5 | 4 | 7 | 29 |
Acquisition of Milestone Education | |||||||||
- | 8 | - | - | - | - | - | - | - | - |
Purchase of intangibles assets-Apad | |||||||||
- | - | 153 | 0 | - | - | - | - | - | - |
Net cash used in investing activities | |||||||||
-9 | -15 | -199 | 8 | - | - | - | -31 | -39 | -108 |
Cash flows from financing activities: | |||||||||
Payments for financing transaction | |||||||||
- | -250 | 250 | 0 | - | - | - | - | - | - |
Proceeds from exercise of warrants | |||||||||
337 | - | - | - | - | - | - | - | - | - |
Consolidation of variable interest entity | |||||||||
- | - | - | 39 | -3,649 | - | - | - | - | - |
Net proceeds from Public Placement Offering | |||||||||
1,974 | - | - | 2,573 | 0 | - | 200 | 150 | - | - |
Net cash used in investing activities | |||||||||
- | - | - | - | -3,727 | -1,304 | -561 | - | - | - |
Repayment of related party loan | |||||||||
- | - | - | - | - | -50 | - | - | - | - |
Capital contribution from noncontrolling interest | |||||||||
- | - | - | - | 500 | 400 | - | - | - | - |
Proceeds from the sale of stock options rights | |||||||||
- | - | - | - | - | - | - | - | 24 | - |
Proceeds from exercise of stock options | |||||||||
- | - | 62 | - | - | 348 | 34 | - | 25 | - |
Net proceeds from Private Placement Offering | |||||||||
250 | - | 150 | 2,225 | 0 | 9,449 | - | - | - | - |
Proceeds from related party loan | |||||||||
- | - | - | - | - | - | 50 | - | - | - |
Net cash provided by financing activities | |||||||||
- | - | - | - | 500 | 10,148 | 284 | - | - | - |
Net decrease in cash and cash equivalents | |||||||||
- | - | - | - | -6,173 | 9,220 | - | - | - | - |
Proceeds from the sale of common stock | |||||||||
- | - | - | - | - | - | - | - | 30 | - |
Net cash provided by financing activities | |||||||||
2,562 | -250 | 463 | 4,798 | - | - | - | 150 | 79 | - |
Net increase (decrease) in cash and cash equivalents | |||||||||
772 | -1,893 | -965 | -592 | - | - | 981 | 68 | -530 | -402 |
Supplemental non-cash disclosure of cash flow information: | |||||||||
Shares issued to employee for bonuses | |||||||||
753 | - | 194 | 389 | - | - | - | - | - | - |
Shares issued to board of directors for services rendered | |||||||||
67 | - | - | - | - | - | - | - | - | - |
Shares issued for conversion of notes payable and accrued interest | |||||||||
- | - | - | - | - | - | 860 | - | - | - |
Shares issued to employees for compensation | |||||||||
37 | 45 | 350 | 366 | - | - | 47 | 43 | 30 | 33 |
Shares issued to consultants in lieu of cash payments | |||||||||
440 | 289 | - | - | - | - | - | - | - | - |
Deferred revenue and accounts receivable, related party adjustment | |||||||||
- | - | 10 | - | - | - | - | - | - | - |
Net assets acquired from variable entity | |||||||||
- | - | - | 16 | 566 | - | - | - | - | - |
Income tax paid | |||||||||
- | - | - | 0 | - | - | - | - | - | - |
Common stock issued for asset acquisition | |||||||||
- | - | 2,486 | 0 | - | - | - | - | - | - |
Sale of Milestone China share, financing transaction | |||||||||
- | -1,400 | 1,150 | 0 | - | - | - | - | - | - |
Credit from United Systems for defective handpieces | |||||||||
151 | - | - | - | - | - | - | - | - | - |
Initial recognition of operating lease-right of use assets | |||||||||
-166 | - | - | - | - | - | - | - | - | - |
Initial recognition of operating lease right to used liabilities | |||||||||
166 | - | - | - | - | - | - | - | - | - |
Operating lease right to used liability | |||||||||
166 | - | - | - | - | - | - | - | - | - |
Shares issued to directors for the exercise of stock options | |||||||||
- | - | - | - | - | - | 34 | - | - | - |
Interest expense paid in cash | |||||||||
- | - | - | - | - | - | - | - | 23 | 92 |
Shares issued to directors for compensation | |||||||||
- | - | - | - | - | - | 45 | 45 | 45 | 45 |
Shares issued to consultants for services | |||||||||
- | - | - | - | - | - | 400 | - | - | - |
Net proceeds on Private Placement Offering | |||||||||
250 | - | 150 | 2,225 | - | - | - | - | - | - |
Shares issued to settle accounts payable | |||||||||
- | - | - | - | - | - | - | 217 | 191 | 104 |
Gain on Dilutive Effect on Medical Joint Venture | |||||||||
- | - | - | - | - | - | 1,363 | - | - | - |
Non-Cash Transfer of assets to JV | |||||||||
- | - | - | - | - | - | - | - | 194 | - |